– USA, CA – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Dr. Lon Cardon (Ph.D. FMedSci) to its Board of Directors, bringing nearly 30 years of extensive industry and academic experience in drug discovery and development.
“We expect Lon’s extensive experience in scientific research and pharmaceutical development to be invaluable in helping Mirum as we grow into a leader in rare disease. We are grateful to Carol for her contributions as a board member and for her new role as an advisor, continuing to support Mirum’s work underway for rare disease patients,” said CEO, Chris Peetz.
Dr. Lon Cardon will also join the Nominating and Governance Committee.
Concurrently, Dr. Carol Brosgart will step down from the Board of Directors
About Dr. Lon Cardon
Dr. Cardon currently serves as president and CEO of The Jackson Laboratory. Before this role, Dr. Cardon was BioMarin’s CSO and chief scientific strategy officer. Before joining BioMarin, he was an SVP at GlaxoSmithKline. He led departments and divisions spanning genetics, molecular biology, computational biology, statistics, and epidemiology, ultimately leading an early-to-late pipeline division called Alternative Discovery and Development. Dr. Cardon spent the first half of his career as a senior academic in the United Kingdom and the United States, initially as a professor of Bioinformatics at the University of Oxford and then as a professor of Biostatistics at the University of Washington, and as co-chair of the Herbold Bioinformatics Program at the Fred Hutchinson Cancer Research Center.
Dr. Cardon received a Ph.D. from the University of Colorado and conducted his post-doctoral research in the Department of Mathematics at Stanford University. He has been awarded a Wellcome Trust Principal Fellowship and is an elected Fellow of the U.K.’s Academy of Medical Sciences and the American Association for the Advancement of Science.
“I am thrilled to join Mirum’s board and am impressed by the company’s scientific prowess, people focus and dedication to improving health outcomes for rare disease communities,” said Dr. Lon Cardon. “I look forward to contributing my experience and passion to helping families impacted by rare diseases while helping guide Mirum as the company executes its global growth strategy in delivering much-needed treatment options to patients.”
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI oral solution which is approved in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. The European Medicines Agency has also granted marketing authorization to Mirum for LIVMARLI to treat cholestatic pruritus in patients with ALGS two months of age and older.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
For more information: https://mirumpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.